UBS Group Raises United Therapeutics (NASDAQ:UTHR) Price Target to $370.00

United Therapeutics (NASDAQ:UTHR) had its price target boosted by UBS Group from $300.00 to $370.00 in a research report released on Monday morning, Benzinga reports. UBS Group currently has a buy rating on the biotechnology company’s stock.

UTHR has been the topic of several other reports. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the company an overweight rating in a report on Wednesday, June 12th. The Goldman Sachs Group boosted their target price on United Therapeutics from $218.00 to $240.00 and gave the company a neutral rating in a research note on Friday, May 3rd. StockNews.com downgraded United Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, June 20th. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an overweight rating in a research report on Tuesday, May 21st. Finally, HC Wainwright reissued a buy rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $318.00.

United Therapeutics Stock Up 2.0 %

NASDAQ UTHR opened at $329.25 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The company has a market capitalization of $14.61 billion, a P/E ratio of 15.57, a PEG ratio of 1.39 and a beta of 0.55. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $329.93. The company’s 50 day simple moving average is $287.54 and its 200 day simple moving average is $248.48.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the company posted $4.86 EPS. Equities research analysts expect that United Therapeutics will post 24.73 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $235.42, for a total transaction of $847,512.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,604.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $235.42, for a total value of $847,512.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,604.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares of the company’s stock, valued at $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold a total of 100,884 shares of company stock worth $27,604,643 over the last 90 days. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at $100,519,000. Swedbank AB acquired a new position in shares of United Therapeutics in the 1st quarter worth approximately $97,316,000. Nordea Investment Management AB raised its holdings in shares of United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after buying an additional 262,222 shares during the last quarter. Avidity Partners Management LP bought a new stake in United Therapeutics during the 4th quarter worth about $52,158,000. Finally, Canada Pension Plan Investment Board lifted its position in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after purchasing an additional 153,700 shares during the period. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.